Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling-Reference-Cited by-同舟云学术

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling

Published:2017-08 Issue: Volume:106 Page:122-132
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Ball Kathryn,Jamier Tanguy,Parmentier Yannick,Denizot Claire,Mallier Agnes,Chenel Marylore

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference33 articles.

1. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations;Abduljalil;Drug Metab. Dispos.,2014

2. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy;Burckhardt,2011

3. Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions;Burt;Eur. J. Pharm. Sci.,2016

4. Evaluation of the drug-drug interaction between zidovudine and probenecid by using a mechanistic kidney model (Mech KiM) nested within a full physiologically based pharmacokinetic (PBPK) model;Crewe,2007

5. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults;Deeks;Antimicrob. Agents Chemother.,1998

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches;Pharmacology Research & Perspectives;2024-07-10

2. Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics;Toxics;2024-06-14

3. Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease;Pharmaceutical Research;2023-09-13

4. Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil;Pharmaceutical Research;2023-01-12

5. Case study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples;Overcoming Obstacles in Drug Discovery and Development;2023